The discovery of lipid and glycolipid antigen recognition by CD1-restricted T cells defi ned a new paradigm for immune recognition and host responses to infection. This is based on the fact that certain cellular and bacterial lipids, which bind to CD1 proteins, are able to activate T lymphocytes (1) . It was also shown that CD1-restricted T cells have an infl uence on the outcome of infections caused by viruses, protozoa, and fungi through the recognition of a great variety of lipids (1, 2) . CD1 molecules are divided into two groups: group 1 contains CD1a, b, and c and group 2 contains CD1d (3). Group 1 CD1s mediate specifi c T cell recognition of mycobacterial lipids (1), whereas CD1d is indispensable for the activation of iNKT cells, a conserved subpopulation of NKT cell, characterized by a canonical Vα24/Jα18 TCR α-chain rearrangement and the preferential usage of Vβ11-chain giving rise to a semiinvariant T cell receptor (4) . This cell type (iNKT) has been proposed to act as a gatekeeper during the earliest stages of the innate immune response controlling DC diff erentiation, NK cell activation, and MHC-restricted T cell polarization (2) .
DCs serve as regulators of immune responses and are considered the most effi cient professional APCs with the unique capability to activate naive T cells (5) . CD1 molecules are diff erentially expressed by various DC subsets; however, the transcription factors or signals that regulate the diff erentiation of these functionally heterogeneous DC types are poorly defi ned. Recently, we reported that the activation of PPARγ, a lipid-activated transcription factor, modulates the phenotype and function of DCs. PPARγ ligand-treated cells acquire higher phagocytic activity, express more CD1d, and display an enhanced capacity to activate iNKT cells than PPAR controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells untreated cells (6) . However, the regulation of CD1d by PPARγ appears to be indirect, because it takes at least 24 h to develop.
In search of downstream mechanisms, we found and documented here that the key enzymes involved in retinoid metabolism are regulated by PPARγ in developing DCs leading to all-trans retinoic acid (ATRA) production. ATRA is a ligand for retinoic acid receptors (RARs) and is generated from retinol, a derivative of vitamin A. Retinol is metabolized intracellularly by alcohol dehydrogenase (ADH) and/or short-chain dehydrogenase/reductases (SDR) to retinal, and subsequently retinal is oxidized by retinal dehydrogenases to retinoid acids (7, 8) . Retinoids have been shown to modulate the immune response by acting on multiple cell types, but the mechanism of their action is still largely elusive. Retinoids are able to modify DC diff erentiation, they promote apoptosis of DCs by an RARα-dependent pathway, and they enhance the maturation of DCs via a retinoid X receptor (RXR)-dependent and an RAR-independent mechanism (9) . A subtype of gut DCs can produce ATRA and regulates T cell homing (10) . Here we describe a mechanism that utilizes PPARγ and RAR signaling pathways in human monocyte-derived DCs to control CD1d expression and iNKT activation in response to lipids.
RESULTS

Activation of PPAR induces the expression of genes involved in retinoic acid biosynthesis
We have characterized the gene expression profi le of PPARγ-activated DCs using Aff ymetrix GeneChips looking for PPARγ-regulated metabolic and signaling pathways. Our global analyses revealed that PPARγ ligand modulates the expression of genes, which participate in lipid metabolism (fatty acid-binding protein [FABP] 4, ADRP, LXRα) and lipid antigen presentation (CD1a, CD1d) in monocyte-derived DCs (6) . Unexpectedly, we observed that several genes involved in all-trans retinoic acid (ATRA) biosynthesis (Fig. 1 A) were also up-regulated by treatment of DCs with rosiglitazone (RSG), a synthetic PPARγ activator ( Fig. 1 B) . All of the identifi ed retinol dehydrogenases, regulated by RSG treatment, are members of the SDR protein family. Several of them catalyze only the reduction of retinal, i.e., DHRS3 (11) , whereas DHRS9 and retinol ARTICLE dehydrogenase (RDH)10 are able to catalyze retinol oxidation (12, 13) and thus may participate in the conversion of retinol to retinal (Fig. 1 A) . The conversion of retinal to ATRA can be catalyzed by retinaldehyde dehydrogenase type 2 (RALDH2), which also appeared to be regulated by PPARγ. These fi ndings prompted us to investigate the relationship of PPARγ, retinoid metabolism, and retinoid signaling in monocyte-derived DCs. First, we validated the enhanced gene expression of retinol dehydrogenases by real-time quantitative PCR (RT-Q-PCR). Elevated levels of mRNA expression of DHRS9 and RDH10 were detected in RSG-treated DCs after 5 d of diff erentiation (Fig. 1, C and D) . To further characterize the onset of enzyme expression, we measured mRNA levels at earlier time-points. We reasoned that for a certain enzymatic reaction to contribute to DC diff erentiation and/ or subtype specifi cation it must be induced early during diff erentiation. Interestingly, only RDH10 was induced as early as 24 h (Fig. 1 D) , suggesting that the PPARγ-regulated component of retinol oxidation might be RDH10. We also looked at the expression of the protein product of this gene and found an elevated level of RDH10 enzyme detected by immunohistochemistry (IHC) (Fig. 1 F) . These results suggested that PPARγ-activated cells are likely to acquire an increased retinol to retinal conversion capacity. Our RT-Q-PCR data also revealed that RALDH2 (also known as ALDH1A2), the enzyme responsible for converting retinal to retinoic acid, was up-regulated upon PPARγ activation (Fig. 1 E) . This eff ect was confi rmed by IHC, which showed elevated protein expression of RALDH (Fig. 1 F) using an anti-RALDH antibody, which can detect RALDH1 or RALDH2. It should be noted that the mRNA expression of RALDH1 was very low in monocyte-derived DCs (unpublished data), suggesting that the detected signal is from RALDH2. Collectively, our results indicated that some key proteins, responsible for bioactive retinoid synthesis, are coordinately up-regulated in PPARγ-instructed DCs.
PPAR instructs DCs to produce ATRA To obtain direct evidence that PPARγ ligand-treated DCs could generate retinoids we determined the intracellular ATRA concentrations by using a sensitive and specifi c liquid chromatography-mass spectrometry (LC-MS) method (14) . Untreated DCs produced very low levels of ATRA, but an elevated amount of ATRA was detected in RSG-treated DCs (Fig. 2 A) . This accumulation appeared to be PPARγ dependent, because a PPARγ antagonist (GW9662) blocked it. The estimated ATRA concentration (0.8-1.2 ng/g cell pellet, equivalent to 2-5 nM) was well within the range to activate RARs (Fig. 2 B) . The concentration of all-trans retinol, the precursor of ATRA, was also determined in the cells, and no diff erence was detected between treated and control samples (20-30 ng/g cell pellet). In addition, a similar retinol concentration was detected in the culture medium (unpublished data). These data strongly suggested that activation of PPARγ leads to ATRA production and potentially to retinoid-regulated gene expression. In other words, it appeared likely that part of the PPARγ-induced changes in gene expression are indeed retinoid mediated. Next, we embarked on evaluating this scenario. The eff ects of retinoids on gene expression are mediated by nuclear receptors (RARs α, β, and γ and RXRs α, β, and γ) (15) . We assessed the transcript levels of these receptors in diff erentiated DCs. We observed that RARα and RXRα were highly expressed, tested both at mRNA (Fig. 2 C) and protein levels (Fig. 2 D) , whereas RXRβ and RARγ were barely detectable. We failed to detect RARβ or RXRγ (unpublished data). These results indicated that the RARα-RXRα heterodimer is likely to be the dominant retinoid receptor in developing DCs. To assess the function of these receptors we monitored the mRNA level of tissue transglutaminase (TGM)2, a well-established retinoid receptor target gene (16) . We examined the eff ects of retinoids in developing DCs by using synthetic and natural RAR agonists. ATRA, a natural ligand of RARs, and AM580, an RARα selective synthetic ligand, strongly induced the expression of TGM2, but the RARγ-specifi c agonist (CD437) did not (Fig. 2 E) . These fi ndings implied that PPARγ-treated DCs produce ATRA, and endogenous accumulation of this compound might trigger the retinoid response by the activation of the RARα nuclear hormone receptor.
Part of PPAR -regulated gene expression is a result of retinoid signaling in DCs
Our data provided several hints that activation of PPARγ induces a retinoid response in human DCs. (a) Key proteins responsible for bioactive retinoid synthesis are up-regulated in PPARγ-instructed DCs. (b) PPARγ ligand-treated cells produce a detectable amount of ATRA. (c) Retinoid target genes, i.e., TGM2 and DHRS3 (17) , were induced by PPARγ ligand (Fig. 1 B and unpublished data) . To assess the contribution of retinoid signaling to the PPARγ response we decided to use a combination of pharmacological activators and inhibitors of these pathways along with an unbiased approach-global gene expression profi ling. Cells were treated with the synthetic PPARγ ligand RSG, or with RSG along with the RARα antagonist (AGN193109), to block RARα-mediated gene expression, or the RARα-specifi c agonists (AM580) alone. This design allows one to determine if retinoid signaling is a downstream event of PPARγ activation and what portion of PPARγ-regulated genes is regulated via induced retinoid signaling. We found that 553 probe sets were signifi cantly changed in a PPARγ-dependent manner (microarray analyses are described in the supplemental Materials and methods, available at http://www.jem.org/cgi/content/full/ jem.20060141/DC1). Datasets are available in the public Gene Expression Omnibus database (accession no. GSE5679). We performed K-means clustering to fi nd characteristic gene expression patterns. Six clusters were generated by this analysis 
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( Fig. 3 A) ; cluster 1 contains probe sets, which were exclusively PPARγ ligand regulated. The RARα antagonist did not decrease and the RARα agonist did not increase the expression of these genes. In this cluster several established PPARγ-responsive genes such as FABP4 and ADRP were found; in addition, the newly identifi ed target gene RDH10 was also in this group. Our quantitative PCR analysis confi rmed that FABP4 and RDH10 were regulated only by PPARγ agonist (Fig. 3 B) . In cluster 3 (see gene list in Table S1 , available at http://www.jem.org/cgi/content/full/jem.20060141/ DC1) gene expression was regulated by both ligands, and the RARα antagonist abolished the eff ect of the PPARγ ligand. As expected, TGM2 was in this cluster, but surprisingly the previously characterized PPARγ-regulated gene, CD1d (6), also fell into this category. These genes appeared to be regulated indirectly by PPARγ via the activation of retinoid signaling. RT-Q-PCR validation of these fi ndings indicated that the gene expression pattern of CD1d was very similar to that of TGM2 (Fig. 3 B) , suggesting that CD1d is indeed regulated in an RARα-dependent manner. We also identifi ed several genes, which were induced independently by either of the two types of ligands (cluster 2). Interestingly, a p450 enzyme, CYP27, was also in this group. We have previously analyzed the promoter region of this gene (18) and have now confi rmed that it is regulated by either PPARγ or RAR. We obtained a similar set of expression patterns when we analyzed the down-regulated genes. Most prominently, cluster 6 contains probe sets of genes down-regulated by PPARγ ligand. This eff ect is abolished in the presence of the RARα antagonist (see gene list in Table S2 , available at http://www.jem.org/cgi/content/full/jem.20060141/DC1). CD1a belong to this group, and the expression of CD1a was confi rmed using RT-Q-PCR. If taken together, our global gene expression profi ling data implies that ‫%03ف‬ of all PPARγ ligand-responsive genes are regulated via the induction of retinoid signaling. Thus, PPARγ-regulated retinoid production signifi cantly contributes to both induced and inhibited gene expression in DCs.
PPAR -mediated CD1d induction requires induced retinoic acid synthesis
The fi nding that RARα antagonist abolished PPARγ ligand-induced CD1d expression suggested that the link between PPARγ and retinoid signaling is likely to be at the level of induced retinoid production. If this argument is correct, increased intracellular ATRA levels should correlate with the expression of CD1d in PPARγ ligand-treated DCs. We have performed time course experiments to address this. As shown in Fig. 4 A, the time course of intracellular ATRA production matches the induction of CD1d, providing further evidence that there is a causative relationship between retinoic acid production and CD1d induction. To gain further mechanistic insights, we used pharmacological means to probe the contribution of enzymatic steps in the regulation of gene expression. We used inhibitors of the enzymatic steps involved in retinoic acid synthesis. Retinal is converted to ATRA by aldehyde dehydrogenases (Fig. 4 B) . This step can be blocked by 4-diethyl amino-benzaldehyde (DEAB) (19) , an inhibitor of RALDHs. ATRA is inactivated by CYP26, a p450 enzyme. This step can be inhibited by R115866, a specifi c CYP26 inhibitor (20) . We used these inhibitors in combination with activators of PPARγ or RARα. As a readout of activation, we measured the expression of the PPARγ target gene FABP4 and the RARα-regulated genes TGM2 and CD1d. We found that PPARγ ligand-mediated induction of CD1d and TGM2 was completely abolished by RALDH inhibitor (DEAB) treatment. Conversely, administration of R115866 (abbreviated as R115) led to an enhanced expression of CD1d (Fig. 4 C) . At the same time DEAB did not abolish the induction of FABP4, indicating that this compound is not a general inhibitor of PPARγ-induced gene expression. We also examined the eff ect of RALDH inhibitor on CD1d and TGM2 expression upon retinoid treatment. When cells were cotreated with the synthetic RARα agonist AM580, DEAB had no eff ect on the induction (Fig. 4 C) . These data provided further support for the argument that endogenously generated ATRA is likely to be responsible for TGM2 and CD1d induction by PPARγ ligands.
CD1d is acutely up-regulated by the activation of the RAR receptor
One of the unanticipated fi ndings of our global gene expression analyses was that both CD1d and CD1a were regulated by PPARγ in an RAR-dependent manner. Next, we wanted to gain more insight into how retinoic acid and its receptor (RARα) regulated CD1d gene expression. First, we compared the time courses of CD1d induction by PPARγ activators and retinoids. We reasoned that if retinoid-induced CD1d expression is downstream of PPARγ, then there must be a shift between the two time courses. It appears to be the case, because activation of RARα induced expression of CD1d already after 1 h, suggesting the involvement of a direct transcriptional event (Fig. 5 A) , whereas PPARγ ligand administration did not up-regulate the expression of CD1d within this time interval as we have previously reported (6) . This expression pattern is consistent with an indirect mechanism triggered by PPARγ activation. The analysis of CD1d expression, however, is complicated by the fact that freshly isolated monocytes also express large amounts of CD1d; thus, it is diffi cult to determine whether retinoids elicit a net induction or block the down-regulation of CD1d. To circumvent this issue we added the activators after 12 h of DC diff erentiation (when CD1d expression is already low). Signifi cantly, we detected an early and robust induction of CD1d by retinoids (Fig. 5 B) . In contrast, to this prompt effect, PPARγ ligand failed to activate this gene after 2 h. To see if retinoids have similar eff ects in cell types other than monocyte-derived DCs we extended our studies into other DC models. We characterized the expression of CD1d in blood DCs. We isolated CD1c + myeloid DCs from monocyte-depleted PBMCs (6) . Cultured blood DCs express low amount of CD1d, but CD1d was highly up-regulated upon retinoid (AM580) treatment (Fig. 5 C) . PPARγ activator was also eff ective albeit much less potent. Based on the evidence presented here, we propose that the eff ect of retinoids on CD1d gene expression is likely to be a "proximal" direct transcriptional event and the PPARγ-dependent regulation of CD1d is indirectly mediated through the activation of retinoid signaling.
Retinoid-treated DCs have an improved lipid presentation capacity
We and others have recently shown that the expression of the CD1 gene family is coordinately regulated by PPARγ activators. PPARγ ligand-treated DCs express a reduced level of CD1a, whereas the level of CD1d is increased upon ligand treatment (6, 21) . Our results presented here argued strongly for the possibility that some of the regulation on CD1 expression is mediated by retinoid signaling. Therefore, we decided to compare the eff ects of retinoids and PPARγ activators on the expression of cell surface molecules of DCs. We sought to characterize the retinoid-regulated events and compare those to PPARγ-regulated processes. First, we looked at the cell surface expression of CD1a and CD1d. 
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Consistent with the mRNA expression pattern membrane, CD1d was up-regulated, whereas CD1a was down-modulated by both RARα and PPARγ ligands (Fig. 6 A) . Importantly and also consistent with the mRNA expression pattern, we observed that RSG-elicited induction of CD1d was abolished by a RALDH inhibitor (DEAB) (Fig. 6 A) . Next, we looked at the functional consequences of retinoid-regulated gene expression. CD1d can present lipid antigens to a specifi c T cell subtype, iNKT cells, which have the potential to regulate both infl ammatory and antiinfl ammatory responses through the rapid secretion of cytokines (4). We assessed the ability of DCs to induce iNKT cell proliferation in autologous mixed leukocyte reaction (MLR) cultures. DCs were loaded with a synthetic CD1d ligand (α-GalCer) (22) for 24 h followed by a co-culture with autologous PBMCs for 5 d. We found that either RARα or PPARγ activation leads to a DC subtype, which has an increased capacity to promote the expansion of iNKT cells (Fig. 6, B and C) . In addition, we also loaded the cells with galactosyl(a1-2) galactosyl-ceramide (GGC), a lipid precursor of the α-GalCer antigen, which requires delivery to the lysosomes where it is hydrolyzed and converted to the active glycolipid (α-GalCer) (23) . PPARγ or RARα receptor agonist-treated DCs elicited an enhanced iNKT expansion when the cells were loaded with this precursor of α-GalCer (Fig. 6 D) , indicating that activation of these pathways enhance the lipid antigen-presenting capacity independent of processing and endosomal loading. To provide further evidence that ligand-instructed DCs could activate iNKT cells we measured INFγ secretion of purifi ed iNKT cells, activated by α-GalCer-loaded DCs, by ELISPOT analysis. We found that both RARα and PPARγ ligandtreated DCs trigger an enhanced INFγ response of iNKT cells (Fig. 6 E) . Our results demonstrated that both PPARγ-and RARα-specifi c ligand-treated DCs express CD1d that is able to present α-GalCer for iNKT cells to elicit their activation. It should be noted that ligand-treated DCs without exogenous glycolipid loading failed to elicit any iNKT cell expansion (Fig. 6, C and D) .
Besides presentation of lipid antigens, DCs are highly active in the presentation of processed peptides by MHC class I and/or class II proteins. The question remained whether activation of either the PPARγ or the RARα pathways had an eff ect on MHC-mediated T cell activation. PPARγ ligandactivated immature DCs exhibit an elevated expression of MHC class II molecules (21) . We confi rmed these results and extended them by phenotyping retinoid (ATRA or AM580)-treated cells in combination with measuring MHC class I (HLA-ABC) membrane expression. Retinoid-treated cells showed a similar HLA-DR expression pattern to PPARγ-activated cells. Both ligands stimulated the cell surface expression of HLA-DR, suggesting that these cells might have a generally enhanced capacity to present peptide antigens (Fig. S1 A, available at http://www.jem.org/cgi/content/ full/jem.20060141/DC1). In contrast to CD1s, the cell surface expression of MHC II was highly up-regulated upon maturation/activation of DCs (24), and it was also suggested that retinoid-treated DCs had a mature/activated phenotype (9, 25) . Consistent with this fi nding we also found that in immature DCs the cell surface expression of HLA-DR was increased upon retinoid treatment, but the bona fi de maturation marker (CD83) was not detected (unpublished data). It is possible that enhanced HLA-DR expression is just a marker of the activation state of these cells, and its expression can be further elevated by proinfl ammatory cytokines. Indeed, we found that mature DCs (MDCs) exhibited elevated expression of HLA-DR, which was not modifi ed by retinoids (Fig. S1 B) . We also investigated the cell surface expression of HLA-ABC and found that both immature and mature DCs express high levels of MHC class I molecules not modifi ed by ligand treatment. To see if activation of RARα had any eff ect on DC-mediated T cell activation we compared the intensity of MLR reactions induced by mature DCs generated with or without RARα or PPARγ agonist. We failed to observe any change in the level of MHC-dependent T cell activation using control or ligand-treated MDCs in an allogeneic MLR test (Fig. S1 C) . We concluded that activation of these nuclear receptors did not confer enhanced antigenpresenting capacity per se, but the activated cells acquired a selectively enhanced NKT cell activating capacity caused by elevated levels of membrane CD1d accompanied by decreased CD1a expression.
Activation of retinoid signaling by natural PPAR activators
Our studies uncovered an interrelated network of lipid signaling processes regulating DC gene expression and function including lipid antigen presentation. An intriguing question remained, however, whether natural sources of PPARγ activators such as oxidized low density lipoprotein (oxLDL) or other lipids (26) were able to elicit retinoid signaling in DCs, providing a biological context and signifi cance for these mechanisms. To test this hypothesis diff erentiating DCs were treated with oxLDL alone or in combination with RAR antagonist or RALDH inhibitor, and the expression pattern of retinoid and PPARγ-regulated genes was measured. oxLDL treatment induced the expression of CD1d, TGM2, and FABP4 (Fig. 7 A) . Treatment with the RAR antagonist and RALDH inhibitor blocked the up-regulation of TGM2 and CD1d, suggesting that retinoid signaling was 100 nM AM580 (AM), 2.5 μM RSG, 1 μM AGN193109 (AGN), 5 μM GW9662, 10 μM DEAB, or 20 μg/ml oxidized low density lipoprotein (oxLDL). The indicated samples were cultured in human AB serum.
involved, but it did not block the up-regulation of FABP4. It is important to note, however, that lipoproteins besides PPARγ activators might also contain retinyl-esters or other retinoid precursors (27, 28) , and these compounds might participate in the activation of retinoid signaling independent of the activation of the PPARγ receptor. To test this we also analyzed the retinoid content of oxLDL by LC-MS. Although we could detect various retinyl-esters, only trace amounts of retinol was found and no ATRA was detected in 100 mg of oxLDL. Our lipid analyses also indicated that several oxidized retinoid species were present (unpublished data). These data imply that oxLDL is likely to contain retinoic acid precursors that can be converted to ATRA inside cells and elicit retinoid signaling. The conversion of this (these) precursor(s) are also, at least in part, under the control of PPARγ. In addition, we have previously defi ned a serum condition (human AB serum), which either contains and/or induces endogenous PPARγ ligands/activators (6). Next we tested if this source of PPARγ activators induced retinoid signaling. In DCs cultured in the presence of human AB serum an elevated level of FABP4, TGM2, and CD1d was detected (Fig. 7 B) . The PPARγ-specifi c antagonist (GW9662) effi ciently decreased the transcript level of all of these genes. Importantly, administration of RAR antagonist or RALDH inhibitor (DEAB) diminished the expression of TGM2 and CD1d but not that of FABP4 (Fig. 7 B) . These experiments collectively demonstrated that activation of PPARγ by biologically relevant normal or pathological serum lipids can also elicit a retinoid response, and it appears likely that in vivo these lipids might be relevant sources of CD1d regulation.
DISCUSSION
Lipid exposure to APCs, including DCs, has fundamental eff ects on their diff erentiation and immune function (2) . The molecular, and in particular, the transcriptional mechanisms contributing to these changes are not well understood. Here we describe a network of regulatory processes involving two lipid-activated transcription factors, PPARγ and RARα, controlling CD1 gene expression and lipid antigen presentation in human developing DCs. Based on the data presented, the following model is emerging: if the lipid environment is permissive for PPARγ receptor activation (i.e., exposure to synthetic PPARγ ligands, oxidized LDL, or human serum), the expression of several genes (RDH10 and RALDH2), acting at subsequent stages of retinoid metabolism, are induced. CD1d along with other retinoid targets gets induced and another set of genes including CD1a is down-modulated (Fig. 8) , bringing about functional changes in lipid antigen-presenting capacity of DCs and iNKT cell activation. The described pathway might be induced by activation of either one or both of the receptors allowing for graded and/or synergistic regulation. As a result, the gene expression pattern and the functions of DCs will be changed depending on the intracellular and extracellular lipid environment.
Regulated production of all-trans retinoic acid in DCs
In vivo, endogenous retinol metabolism is a tightly controlled process (7, 8) ; however, it is largely unknown which type of immune cells are able to generate the active form of vitamin A. It was recently shown that murine intestine-associated DCs could produce retinoids, but DCs from other tissues failed to produce ATRA (10) . In addition, several retinol/retinal metabolizing enzymes were detected in intestinal DCs. In our studies, we identifi ed several genes participating in retinoid metabolism in human DCs, which had an increased expression level in cells treated with PPARγ acti vators. Time course experiments and receptor selective inhibitors helped to establish that PPARγ acted upstream of retinoid signaling. One of the regulated steps, RDH10 expression and activity, can initiate ATRA production in a PPARγ-dependent manner. We also observed that the expression of RALDH2 was highly increased during DC development, and PPARγ ligandtreated cells showed a further elevated level. Therefore, it is very likely that RALDH2 is required for the enhanced production of ATRA. These data also suggest that retinoid production is not an inherent characteristic of DCs but an acquired/regulated one. Our data support a model for such controlled retinoid production and signaling in human DCs and suggests that ligand activation of PPARγ is acting as one of the regulators. In our case, ‫%03ف‬ of the gene expression changes are caused by induced retinoid signaling. Besides CD1d, several other transcripts get up-regulated in this way (i.e., DHRS3, fi bronectin, TGM2), suggesting that this regulatory mechanism can modulate other pathways that might have roles in DC function.
Biological roles for PPAR -controlled retinoid production
It is also conceivable that the produced lipid mediators such as retinoids are exported from the cells and modify the function of exposed neighboring cells. DCs interact with almost all types of immune cells and are important regulators of both adaptive and innate immune responses while controlling immunological tolerance. DCs collaborate also with epithelial cells, and much of their eff ects are implemented at the interface of DC and lymphocytes. Retinoids have been shown to have a profound eff ect on T cell activation (29) . One could speculate that locally generated ATRA by PPARγ-activated DCs, besides acting in DCs, if exported, might also infl uence the functions of local cells, such as epithelial cells (30, 31) , monocytes, and B and T lymphocytes. It is also plausible that the small intestine is the place where intense lipid traffi c occurs and PPARγ activators can be generated. We have preliminary data to suggest that some of the DCs of Peyer's patches are PPARγ positive, and these cells also express RALDH and are likely to generate retinoids in a regulated manner. Remarkably, all the PPARγ positive cells coexpress TGM2, a bona fi de retinoid target gene, strongly suggesting that these cells have active retinoid signaling and that PPARγ-positive DCs in Peyer's patches is an in vivo identifi able and thus relevant cell type (unpublished data).
The regulatory effects of exogenous lipids from physiological and pathological sources Mediators (such as oxLDL, prostaglandins, and other serum lipids) of PPARγ activation might switch on this pathway leading to retinoid generation provided that precursors are also present. In fact, we observed that oxLDL promoted CD1d induction in human DCs via activation of retinoid signaling. It is very intriguing to speculate that turning on the lipidpresenting molecule CD1d and lipid antigen production and presentation might also be linked. It was recently shown that lipoproteins can promote the delivery of exogenous glycolipid antigens to the CD1d antigen-loading compartments in human DCs (23) . It is possible that oxLDL also participates in this process; therefore, in addition to the induction of CD1d, oxLDL might also modulate the uptake of glycolipid antigens in these cells. Interestingly and in agreement with this model, it was also shown that oxLDL in murine peritoneal macrophage elicits CD1d induction and that CD1d-dependent iNKT activation has a proatherogenic eff ect (32, 33) . These data are consistent with our previous results on PPARγ-mediated CD1d regulation and with the data presented here.
The transcriptional regulation of CD1d and CD1a appears to be coupled and inverse
We have shown previously that ligand activation of PPARγ induced CD1d and inhibited CD1a expression. Now by identifying the proximal mechanism we have found that activation of the RAR has an eff ect similar to that of PPARγ on CD1a and CD1d expression. These two molecules belong to group 1 (CD1a) and group 2 (CD1d) CD1 proteins. There are emerging lines of evidence to suggest that the timing of their expression, the mode of their regulation, and function may also be diff erent. Group 1 CD1s are not expressed in monocytes and other myeloid precursors but are induced upon DC differentiation. It has also been suggested that myeloid cells such as DCs express group 1 CD1 mRNA and proteins as a result of contact with pathogens such as mycobacteria, TLR agonists, or cytokines (34) . In contrast to group I CD1 molecules, the expression of CD1d can be increased by viruses and bacteria and by activators of PPARγ. It is also intriguing that a single microbial stimulus (i.e., mycobacterial lipids) can oppositely regulate group 1 and group 2 CD1s (34). Our data presented here is very much in line with this scenario and suggests that depending on the actual lipid environment, the activation of either PPARγ and/or RAR would regulate CD1d and CD1a in opposite directions. This hypothesis is further supported by two additional notions. One is that CD1a and CD1d have distinct functions caused by dissociable and opposite regulation. The second is that certain lipids present in the immune milieu might contribute to changing CD1 expression to arm the cell with the needed CD1 species for presenting lipids the cell become exposed to because of the altered lipid environment (2) . Our studies identifi ed lipids such as oxLDL, normal human serum, and retinoids as lipid species regulating CD1 expression. Some of these contain activators or precursors of activators for PPARγ, RAR, or both. The functional consequence of this is that the presence of PPARγ-activating lipids or retinoic acid would dictate CD1 expression during DC diff erentiation, leading to a CD1d-positive and CD1a-negative potentially antiinfl ammatory cell, or the lack of these lipids and/or the presence of other lipids would promote the diff erentiation of a CD1a-positive and CD1d-negative cell responding to the attack of infectious agents (i.e., mycobacteria). Thus, the regulated production of retinoic acid appears to be a key mediator of this process and a determinant of CD1 expression in developing DCs. This eff ect appears to be specifi c for modifying lipid antigen presentation capacity and has little or no infl uence on MHC-mediated antigen presentation.
In summary, our fi ndings provide molecular insights into the regulatory logic and the interrelatedness of lipid signaling (retinoid and fatty acid) and lipid antigen presentation. These pathways might also be amenable for therapeutic intervention in infl ammatory and immune diseases.
MATERIALS AND METHODS
Ligands. Cells were treated with the following ligands: AM580 (Biomol), rosiglitazone and GW9662, (Alexis Biochemicals), and AGN193109 (a gift from R.A.S. Chandraratna, Allergan Inc., Irvine CA). oxLDL was obtained from Intracel, R115866 was obtained from Janssen, DEAB was obtained from Fluka, and α-GalCer was obtained from Kirin Brewery Ltd. GGC was described previously (23) .
Cell culture and ligand treatment. Monocytes (98% CD14 + ) were obtained from Buff y coats by Ficoll gradient centrifugation and magnetic cell separation using anti-CD14-conjugated microbeads (VarioMACS; Miltenyi Biotec). DCs were prepared as described previously (6) with minor modifications. In brief, monocytes were resuspended into six-well culture dishes at a density of 1.5 × 10 6 cells/ml and cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% FBS (Invitrogen) containing 800 U/ml GM-CSF (Peprotech) and 500 U/ml IL-4 (Peprotech). In some experiments, FBS was replaced with human AB serum (Sigma-Aldrich). Cells were cultured for 5 or 6 d, and the IL-4 and GM-CSF addition was repeated at day 3. Ligands or vehicle control (50% DMSO/ethanol) were added to the cell culture starting from the fi rst day or otherwise indicated. AGN193109 administration was always repeated at day 3. To obtain MDCs, DCs were treated with the following mix of cytokines for 24 h: 10 ng/ml TNF-α, 10 ng/ml IL-1β, 1,000 U/ml IL-6 (Peprotech), and 1 μg/ml PGE 2 (Sigma-Aldrich).
